Drug Profile
Research programme: cancer and antiviral therapeutics - Syntonix
Alternative Names: Interferon-α-Fc; T20-FcLatest Information Update: 25 Feb 2008
Price :
$50
*
At a glance
- Originator Syntonix Pharmaceuticals
- Class Interferons
- Mechanism of Action HIV fusion inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Hepatitis C; HIV infections
Most Recent Events
- 01 Feb 2007 Syntonix Pharmaceuticals has been acquired by Biogen Idec
- 23 Aug 2004 Preclinical trials in Cancer in USA (unspecified route)
- 23 Aug 2004 Preclinical trials in Hepatitis C treatment in USA (unspecified route)